Lunit and 10x Genomics will link pathology images to spatial molecular data

Lunit is working with 10x Genomics to connect what a tumour looks like under the microscope with what is happening in its genes at specific spots in the tissue. The goal is finding markers that predict whether a treatment will work. This is research only, and Lunit says so on the page.

By Atlas ... AI Editorial Collaborator

What Lunit and 10x Genomics Announced About Spatial Pathology Research

Lunit announced on September 10, 2026 a collaboration with 10x Genomics to combine Lunit SCOPE IO, its AI analysis of standard stained pathology slides, with 10x Genomics Xenium and Atera spatial platforms. The stated aim is to better understand how tissue appearance relates to the underlying biology of tumours, and to identify biomarkers associated with treatment response and resistance. The announcement carries an explicit disclaimer that Lunit SCOPE IO is for research use only and not for use in diagnostic procedures. Lunit describes the SCOPE platform as used in research partnerships with pharmaceutical and laboratory organisations for biomarker research and companion diagnostic development, separately from its FDA-cleared INSIGHT Breast Suite.

Why the Lunit 10x Genomics Work Matters to Oncology Research Teams

This is the quieter half of Lunit's business and the one that pays differently. Screening AI sells to hospitals at hospital prices, while biomarker work sells to pharmaceutical companies developing drugs, which is a smaller number of much larger contracts. For a research team the practical appeal is skipping a step, since a cheap stained slide read by AI may flag what would otherwise need expensive spatial sequencing. Read the research use only label literally: nothing here is for diagnosing a patient.

Where the Lunit Update Comes From

Lunit is the original record behind this update. It tells us what the company published. This brief adds the market context and the method we would use to test the development against other evidence.

Lunit original source.

How We Would Research the Lunit 10x Genomics Collaboration

The source gives us the starting point. This is how we would build the next layer of research around it.

We would start by asking which specific tumour types and drug programs the collaboration is being used on today.
Then we would look for published work showing SCOPE IO predictions holding up against the spatial molecular data.
We would ask how Lunit is paid for this work, since pharmaceutical research revenue behaves very differently from hospital software revenue.